{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:12:45Z","timestamp":1777489965643,"version":"3.51.4"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1097\/fpc.0000000000000348","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:52:37Z","timestamp":1535935957000},"page":"199-206","source":"Crossref","is-referenced-by-count":6,"title":["Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients"],"prefix":"10.1097","volume":"28","author":[{"given":"Sarah","family":"Allegra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"De Francia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Massano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Avataneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"De Nicol\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D\u2019Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210213","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"key":"R2-1-20210213","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1182\/blood-2005-02-0460","article-title":"Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells","volume":"106","author":"Glickstein","year":"2005","journal-title":"Blood"},{"key":"R3-1-20210213","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2006-05-020867","article-title":"Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences","volume":"108","author":"Glickstein","year":"2006","journal-title":"Blood"},{"key":"R4-1-20210213","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1124\/dmd.109.030833","article-title":"Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state","volume":"38","author":"Waldmeier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R5-1-20210213","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1124\/dmd.108.022962","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats","volume":"36","author":"Bruin","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R7-1-20210213","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4615-0593-8_10","article-title":"ICL670A: preclinical profile","volume":"509","author":"Nick","year":"2002","journal-title":"Adv Exp Med Biol"},{"key":"R8-1-20210213","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2174\/0929867033457610","article-title":"Development of tridentate iron chelators: from desferrithiocin to ICL670","volume":"10","author":"Nick","year":"2003","journal-title":"Curr Med Chem"},{"key":"R9-1-20210213","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2009-05-222729","article-title":"Deferasirox pharmacokinetics in patients with adequate versus inadequate response","volume":"114","author":"Chirnomas","year":"2009","journal-title":"Blood"},{"key":"R10-1-20210213","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/tpj.2014.65","article-title":"Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness","volume":"15","author":"Cusato","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"R11-1-20210213","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2217\/pgs-2015-0001","article-title":"Role of pharmacogenetic on deferasirox AUC and efficacy","volume":"17","author":"Cusato","year":"2016","journal-title":"Pharmacogenomics"},{"key":"R12-1-20210213","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00228-016-2070-9","article-title":"Deferasirox AUC efficacy cutoff and role of pharmacogenetics","volume":"72","author":"Allegra","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"R13-1-20210213","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00198-015-3264-1","article-title":"A 2-year prospective densitometric study on the influence of Fok-I gene polymorphism in young patients with thalassaemia major","volume":"27","author":"Dimitriadou","year":"2016","journal-title":"Osteoporos Int"},{"key":"R14-1-20210213","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1651-2227.1997.tb08940.x","article-title":"Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in beta-thalassaemia","volume":"86","author":"Moulas","year":"1997","journal-title":"Acta Paediatr"},{"key":"R15-1-20210213","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bone.2005.11.018","article-title":"Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia","volume":"38","author":"Napoli","year":"2006","journal-title":"Bone"},{"key":"R16-1-20210213","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1365-2141.2008.07135.x","article-title":"Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major","volume":"141","author":"Wood","year":"2008","journal-title":"Br J Haematol"},{"key":"R17-1-20210213","doi-asserted-by":"crossref","first-page":"e2013057","DOI":"10.4084\/mjhid.2013.057","article-title":"Vitamin d status in thalassemia major: an update","volume":"5","author":"Soliman","year":"2013","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R18-1-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2012.03.003","article-title":"Vitamin D: metabolism","volume":"38","author":"Christakos","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"R19-1-20210213","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/281317a0","article-title":"1 alpha, 25-Dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in vitro synthesis by human decidua and placenta","volume":"281","author":"Weisman","year":"1979","journal-title":"Nature"},{"key":"R20-1-20210213","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.451538","article-title":"Evidence for extra-renal 1 alpha-hydroxylation of 25-hydroxyvitamin D3 in pregnancy","volume":"204","author":"Gray","year":"1979","journal-title":"Science"},{"key":"R21-1-20210213","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jsbmb.2006.12.091","article-title":"Immune regulation of 1alpha-hydroxylase in murine peritoneal macrophages: unravelling the IFNgamma pathway","volume":"103","author":"Stoffels","year":"2007","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R22-1-20210213","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jsbmb.2004.03.092","article-title":"1alpha-Hydroxylase transactivation by gamma-interferon in murine macrophages requires enhanced C\/EBPbeta expression and activation","volume":"89-90","author":"Esteban","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R23-1-20210213","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1210\/mend.16.6.0874","article-title":"Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation","volume":"16","author":"Lin","year":"2002","journal-title":"Mol Endocrinol"},{"key":"R24-1-20210213","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1152\/physiolgenomics.00002.2003","article-title":"DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line","volume":"17","author":"Wood","year":"2004","journal-title":"Physiol Genomics"},{"key":"R25-1-20210213","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1210\/me.2005-0106","article-title":"Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes","volume":"19","author":"Wang","year":"2005","journal-title":"Mol Endocrinol"},{"key":"R26-1-20210213","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/tpj.2017.43","article-title":"Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes","volume":"18","author":"Allegra","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"R27-1-20210213","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/FPC.0000000000000315","article-title":"Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children","volume":"28","author":"Allegra","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"R28-1-20210213","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2002-06-1723","article-title":"Noninvasive measurement of iron: report of an NIDDK workshop","volume":"101","author":"Brittenham","year":"2003","journal-title":"Blood"},{"key":"R29-1-20210213","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2141.2004.04838.x","article-title":"Evaluation of iron overload","volume":"124","author":"Jensen","year":"2004","journal-title":"Br J Haematol"},{"key":"R30-1-20210213","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1182\/blood-2002-09-2754","article-title":"Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool","volume":"101","author":"Jensen","year":"2003","journal-title":"Blood"},{"key":"R31-1-20210213","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2141.2004.05195.x","article-title":"Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia","volume":"127","author":"Kolnagou","year":"2004","journal-title":"Br J Haematol"},{"key":"R32-1-20210213","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2012.02.047","article-title":"A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients","volume":"893-894","author":"De Francia","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R33-1-20210213","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/aje\/kwn359","article-title":"Hardy\u2013Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies","volume":"169","author":"Rodriguez","year":"2009","journal-title":"Am J Epidemiol"},{"key":"R34-1-20210213","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/35075590","article-title":"Linkage disequilibrium in the human genome","volume":"411","author":"Reich","year":"2001","journal-title":"Nature"},{"key":"R35-1-20210213","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/nar\/19.17.4797","article-title":"PCR detection of an A\/G polymorphism within exon 7 of the CYP1A1 gene","volume":"19","author":"Hayashi","year":"1991","journal-title":"Nucleic Acids Res"},{"key":"R36-1-20210213","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0014-5793(90)80721-T","article-title":"Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene","volume":"263","author":"Kawajiri","year":"1990","journal-title":"FEBS Lett"},{"key":"R37-1-20210213","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1383-5742(03)00016-4","article-title":"Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism","volume":"544","author":"Mitrunen","year":"2003","journal-title":"Mutat Res"},{"key":"R38-1-20210213","first-page":"1509","article-title":"Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer","volume":"12","author":"Hashibe","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R39-1-20210213","doi-asserted-by":"crossref","first-page":"e895","DOI":"10.1097\/MD.0000000000000895","article-title":"Association of CYP1A1 and GSTM1 polymorphisms with oral cancer susceptibility: a meta-analysis","volume":"94","author":"Liu","year":"2015","journal-title":"Medicine (Baltimore"},{"key":"R40-1-20210213","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2217\/pgs-2015-0001","article-title":"Role of pharmacogenetics on deferasirox AUC and efficacy","volume":"17","author":"Cusato","year":"2016","journal-title":"Pharmacogenomics"},{"key":"R41-1-20210213","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2133\/dmpk.DMPK-11-RV-098","article-title":"Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)","volume":"27","author":"Ieiri","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R42-1-20210213","first-page":"1","article-title":"Human ABCG2: structure, function, and its role in multidrug resistance","volume":"3","author":"Mo","year":"2012","journal-title":"Int J Biochem Mol Biol"},{"key":"R43-1-20210213","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.18632\/oncotarget.1050","article-title":"High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients","volume":"4","author":"Delord","year":"2013","journal-title":"Oncotarget"},{"key":"R44-1-20210213","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/jid.2008.16","article-title":"Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis","volume":"128","author":"Warren","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R45-1-20210213","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/pgs-2016-0176","article-title":"Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients","volume":"18","author":"Allegra","year":"2017","journal-title":"Pharmacogenomics"},{"key":"R46-1-20210213","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-014-1801-z","article-title":"Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"R47-1-20210213","doi-asserted-by":"crossref","first-page":"e0134102","DOI":"10.1371\/journal.pone.0134102","article-title":"Association of ABCB1 and FLT3 polymorphisms with toxicities and survival in Asian patients receiving sunitinib for renal cell carcinoma","volume":"10","author":"Chu","year":"2015","journal-title":"PLoS One"},{"key":"R48-1-20210213","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/bcp.12654","article-title":"Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene","volume":"80","author":"Gotanda","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R49-1-20210213","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/pgs.09.85","article-title":"Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin","volume":"10","author":"Keskitalo","year":"2009","journal-title":"Pharmacogenomics"},{"key":"R50-1-20210213","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R51-1-20210213","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/FPC.0000000000000022","article-title":"Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line","volume":"24","author":"Skoglund","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R52-1-20210213","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/35103535","article-title":"Accessing genetic variation: genotyping single nucleotide polymorphisms","volume":"2","author":"Syvanen","year":"2001","journal-title":"Nat Rev Genet"},{"key":"R53-1-20210213","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/pros.21180","article-title":"Vitamin D pathway gene variants and prostate cancer prognosis","volume":"70","author":"Holt","year":"2010","journal-title":"Prostate"},{"key":"R54-1-20210213","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/pcan.2014.1","article-title":"Genetic variants in the CYP24A1 gene are associated with prostate cancer risk and aggressiveness in a Korean study population","volume":"17","author":"Oh","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R55-1-20210213","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3851\/IMP2853","article-title":"Vitamin D pathway gene variants and HCV-2\/3 therapy outcomes","volume":"20","author":"Cusato","year":"2014","journal-title":"Antivir Ther"},{"key":"R56-1-20210213","doi-asserted-by":"crossref","first-page":"171","DOI":"10.18433\/J3DK6T","article-title":"Intracellular and plasma trough concentration and pharmacogenetics of telaprevir","volume":"18","author":"Cusato","year":"2015","journal-title":"J Pharm Pharm Sci"},{"key":"R57-1-20210213","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijpharm.2015.11.044","article-title":"Ethambutol plasma and intracellular pharmacokinetics: a pharmacogenetic study","volume":"497","author":"Fatiguso","year":"2015","journal-title":"Int J Pharm"},{"key":"R58-1-20210213","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1301\/nr.2007.aug.S96-S101","article-title":"What are the frequency, distribution, and functional effects of vitamin D receptor polymorphisms as related to cancer risk?","volume":"65","author":"Rukin","year":"2007","journal-title":"Nutr Rev"},{"key":"R59-1-20210213","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.gene.2004.05.014","article-title":"Genetics and biology of vitamin D receptor polymorphisms","volume":"338","author":"Uitterlinden","year":"2004","journal-title":"Gene"},{"key":"R61-1-20210213","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nrd3318","article-title":"Vitamin D, disease and therapeutic opportunities","volume":"9","author":"Plum","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"R62-1-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-386960-9.00001-0","article-title":"Vitamin D regulation of immune function","volume":"86","author":"Bikle","year":"2011","journal-title":"Vitam Horm"},{"key":"R63-1-20210213","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/FPC.0b013e328354455c","article-title":"Very important pharmacogene summary for VDR","volume":"22","author":"Poon","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R64-1-20210213","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.humimm.2010.12.010","article-title":"Vitamin D receptor gene methylation is associated with ethnicity, tuberculosis, and TaqI polymorphism","volume":"72","author":"Andraos","year":"2011","journal-title":"Hum Immunol"},{"key":"R65-1-20210213","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/pgs-2017-0176","article-title":"Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics","volume":"18","author":"Allegra","year":"2017","journal-title":"Pharmacogenomics"},{"key":"R66-1-20210213","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bcp.2008.05.030","article-title":"Identification of the functional vitamin D response elements in the human MDR1 gene","volume":"76","author":"Saeki","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"R67-1-20210213","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ajh.2830420116","article-title":"Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major","volume":"42","author":"Brittenham","year":"1993","journal-title":"Am J Hematol"},{"key":"R68-1-20210213","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000243801","article-title":"Deferasirox (Exjade) for the treatment of iron overload","volume":"122","author":"Cappellini","year":"2009","journal-title":"Acta Haematol"},{"key":"R69-1-20210213","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12968-015-0118-0","article-title":"Myocardial T2 mapping reveals age- and sex-related differences in volunteers","volume":"17","author":"Bonner","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"key":"R70-1-20210213","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/jphp.12559","article-title":"Deferasirox pharmacokinetic evaluation in beta-thalassaemia paediatric patients","volume":"69","author":"Allegra","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"R71-1-20210213","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/jphp.12638","article-title":"Deferasirox pharmacokinetic and toxicity correlation in beta-thalassaemia major treatment","volume":"68","author":"Allegra","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"R72-1-20210213","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.biopha.2016.11.041","article-title":"Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous beta-thalassaemia","volume":"84","author":"Allegra","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"R73-1-20210213","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/1440-1681.12879","article-title":"Clinical relevance of deferasirox trough levels in beta-thalassemia patients","volume":"45","author":"Allegra","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:24:28Z","timestamp":1620951868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201809000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":71,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000348","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}